Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ovarian Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ovarian Cancer
    TopAbstracts in Ovarian Cancer 07/01/2009 - (DGNews)
    Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary - (N Engl J Med)
    Delayed Symptom Progression, Better Tolerability Found With Pegylated Liposomal Doxorubicin Plus Carboplatin for Ovarian Cancer: Presented at ASCO - (DGDispatch)
    TopAbstracts in Ovarian Cancer 06/03/2009 - (DGNews)
    TopAbstracts in Ovarian Cancer 05/06/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Ovarian Cancer
    • Current Therapeutic Options and Clinical Issues in Recurrent Ovarian Cancer: Where Do We Stand?
    • Looking Ahead: Emerging Options in Treatment of Ovarian Cancer
    • Ovarian Cancer: Designed for the Primary Care Physician
      Gynecologic and Colorectal Cancer: Risks and Benefits of Contraceptive Methods

      Webcasts/CME archive

       Recent cases - Ovarian Cancer
        Choroidal Eye Metastases from (Recurrent) Primary Peritoneal Carcinoma: Case Report and Review of the Literature
        A Case of Meigs Syndrome Mimicking Metastatic Breast Carcinoma
        Uterine Tumours Resembling Ovarian Sex Cord Tumours: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
        Ruptured Ovarian Cystic Teratoma in Pregnancy with Diffuse Peritoneal Reaction Mimicking Advanced Ovarian Malignancy: A Case Report

        Cases archive
          




        my personal edition > ovarian cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Bowel Involvement in Advanced Ovarian Cancer Not a Predictor of Poor Outcome: Presented at SSO

        By Mary Beth Nierengarten

        CHICAGO -- March 18, 2008 -- Bowel involvement in patients with advanced epithelial ovarian cancer should not preclude a radical bowel resection at the time of tumour debulking to achieve optimal cytoreduction, according to research presented here at the Society of Surgical Oncology (SSO) 61st Annual Cancer Symposium.

        "Patients with [ovarian cancer and] bowel involvement who get optimal care have outcomes that are no different than for patients without bowel involvement," said lead author Saad Sirop, MD, Resident, McLaren Regional Medical Center, Flint, Michigan.

        According to Dr. Sirop, the role of radical resection to achieve optimal cytoreduction in patients with stage III or IV ovarian cancer remains controversial. Although there is a shift toward including a bowel resection in these patients, there is still concern about the potential for increasing complications without additional benefit.

        To assess the safety of radical bowel resection and its effect on recurrence and survival in patients with advanced ovarian cancer, Dr. Sirop and colleagues retrospectively reviewed the data of 92 consecutive patients with stage II to IV epithelial ovarian cancer treated between 1991 and 2006. The authors compared 2 groups of patients: those who had bowel resection at the time of primary debulking surgery (n = 48) (group A) and those who did not have bowel involvement and did not undergo a bowel resection (n = 44) (group B).

        In group A, 5 patients (10%) had stage II disease, 38 (79%) had stage III disease, and 5 (10%) had stage IV disease. In group B, 6 patients (13%) had stage II, 30 (68%) had stage III disease, and 8 (18%) had stage IV disease. The 5 stage II patients in group A underwent bowel resection because of concomitant adhesions.

        For both groups, the most common histological type of tumour was serous papillary carcinoma, identified in 48% of patients in group A and 91% in group B.

        The types of bowel resection performed on the group A patients were as follows: large-bowel resection (67%), small-bowel resection (10%), gastrectomy (10%), and combined small- and large-bowel resection (12%).

        In both groups, there was no difference in survival outcome (median overall survival, disease-free survival, and recurrence-free survival) between stage II, III, and IV disease. In addition, no difference was found between groups A and B in optimal cytoreduction rates (79% vs 82%, P = .79).

        Overall, bowel continuity was maintained in 77% of the patients in group A; there was no perioperative mortality, and the most common morbidity was prolonged postoperative ileus.

        In addition to evaluating the role of radical bowel resection in these patients, the study also examined the role of neoadjuvant chemotherapy as initial management for advanced disease in patients with bowel involvement at the time of diagnosis, which, according to Dr. Sirop, is an even more controversial issue.

        The study found optimal cytoreduction in group A patients who underwent neoadjuvant chemotherapy followed by surgery versus those who underwent primary surgery with bowel resection without neoadjuvant chemotherapy (85% vs 62%, P = .08). Survival rates, however, were similar (27 vs 25 months, respectively).

        According to Dr. Sirop, patients with bulkier disease were selected for neoadjuvant chemotherapy, and this selection bias may be a contributing factor to the lack of survival difference.

        Dr. Sirop recommended consideration of neoadjuvant chemotherapy at the time of diagnosis in patients with bowel involvement.

        Based on these study results, Dr. Sirop concluded that "bowel involvement is not in itself a poor prognostic factor."


        [Presentation title: The Impact of Radical Bowel Resection During Primary Surgery on the Recurrence and Survival in Epithelial Ovarian Cancer. Abstract P219]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send